Press release
Metachromatic Leukodystrophy Pipeline Therapeutics Review 2018
Metachromatic leukodystrophy (MLD) is an inherited disease that causes fat accumulation in cells. The disease affects the nervous system which produces myelin sheath for insulation and protection of nerves. The fatty deposition, called sulfatides in nerve cells causes the destruction of white matter, which is formed by myelin sheath. It further deteriorates the cognitive functioning of nerves such as an ability to walk, loss of sensation (also known as peripheral neuropathy), seizure, incontinence, inability to speak, paralysis, hearing loss, and blindness. The late infantile form is the common form of metachromatic leukodystrophy that affects in the second year of life and causes loss of speech, gait disturbances and weakness in children. In patients with metachromatic leukodystrophy, the mutation in ARSA gene causes the deficiency of the enzyme, arylsulfatase A, which helps in breakdown of sulfatides. This leads to accumulation of sulfatides in nerve cells. The Shenzhen University is in the process of developing transduced CD34+ hematopoietic stem cell for the treatment of metachromatic leukodystrophy. The University of Minnesota is in the process of developing stem cell transplantation for the treatment of metachromatic leukodystrophy. Some of the companies having the pipeline of metachromatic leukodystrophy include Shire plc, GlaxoSmithKline plc, Zymenex A/S and others.Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/mld-therapeutics-pipeline-analysis/report-sample
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
Explore Report at: https://www.psmarketresearch.com/market-analysis/mld-therapeutics-pipeline-analysis
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metachromatic Leukodystrophy Pipeline Therapeutics Review 2018 here
News-ID: 974205 • Views: …
More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of…

Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis
Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where…

Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis
The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the…

Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market
As per the findings of research, it…
More Releases for Metachromatic
Metachromatic Leukodystrophy Treatment Market to Exceed USD 479.51 Million by 20 …
Metachromatic leukodystrophy (MLD) is a rare but devastating genetic disorder that primarily affects children and leads to progressive deterioration of the nervous system. Historically, the absence of effective treatment options and the rapid progression of the disease left families with few avenues for intervention. However, recent breakthroughs in gene therapy, enzyme replacement therapy (ERT), and early diagnostic screening have changed the landscape dramatically.
Download Full PDF Sample Copy of Market Report…
Metachromatic Leukodystrophy Pipeline Insight 2025: Advancing Gene Therapies and …
DelveInsight's "Metachromatic Leukodystrophy - Pipeline Insight, 2025" report delivers a detailed overview of the therapeutic development landscape targeting this rare, inherited lysosomal storage disorder caused by arylsulfatase A (ARSA) deficiency. Characterized by progressive demyelination affecting the central and peripheral nervous systems, Metachromatic Leukodystrophy (MLD) often leads to severe motor and cognitive decline, with limited treatment options available until recently.
In 2025, the MLD pipeline is dominated by advanced gene therapies and…
Metachromatic Leukodystrophy Treatment Market | Latest Therapies, Growth Trends …
The Metachromatic Leukodystrophy Treatment Market is estimated to reach at a CAGR of 6.3% during the forecast period (2024-2031).
The Metachromatic Leukodystrophy Treatment Market, as examined in the DataM Intelligence study, offers a comprehensive overview of the industry, enriched with in-depth insights, historical data, and key statistics. The report provides a thorough analysis of market dynamics, competitive strategies, and leading players, detailing their product offerings, pricing models, financial performance, expansion strategies,…
Metachromatic leukodystrophy Treatment Market Focusing on Trends and Innovations …
The Metachromatic leukodystrophy Treatment Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.
Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/metachromatic-leukodystrophy-treatment-market
What is the…
Metachromatic Leukodystrophy Treatment Market is expected to show growth from 20 …
Metachromatic Leukodystrophy Treatment Market was valued at USD 3.53 Bn. in 2023 and is expected to reach USD 7.06 Bn. by 2030, at a CAGR of 10.4% over the forecast period (2024-2030).
Metachromatic Leukodystrophy Treatment Market Overview
Metachromatic leukodystrophy (MLD) is a rare genetic disorder caused by a deficiency of the enzyme arylsulfatase A, which is vital for maintaining myelin, the protective layer around nerve fibers. Without this enzyme, myelin deteriorates,…
Metachromatic Leukodystrophy Pipeline, FDA Approvals, Clinical Trials Developmen …
DelveInsight's, "Metachromatic Leukodystrophy Pipeline Insight 2024" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Metachromatic Leukodystrophy pipeline landscape. It covers the Metachromatic Leukodystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metachromatic Leukodystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Metachromatic Leukodystrophy…